TY - JOUR
T1 - Serum oxidized protein and prostate cancer risk within the prostate cancer prevention trial
AU - Hoque, Ashraful
AU - Ambrosone, Christine B.
AU - Till, Cathee
AU - Goodman, Phyllis J.
AU - Tangen, Cathy
AU - Kristal, Alan
AU - Lucia, Scott
AU - Wang, Qiao
AU - Kappil, Maya
AU - Thompson, Ian
AU - Hsing, Ann W.
AU - Parnes, Howard
AU - Santella, Regina M.
PY - 2010/4
Y1 - 2010/4
N2 - To evaluate the role of oxidative stress in prostate cancer risk, we analyzed serum levels of protein carbonyl groups in 1,808 prostate cancer cases and 1,805 controls, nested in the Prostate Cancer Prevention Trial, a randomized, placebo-controlled trial that found finasteride decreased prostate cancer risk. There were no significant differences in protein carbonyl levels in baseline samples between those later diagnosed with prostate cancer and those without at the end of study biopsy. Adjusted odds ratios and 95% confidence intervals (95% CI) for the 4th quartile of protein carbonyl level for the combined, placebo, and finasteride arms were 1.03 (95% CI, 0.85-1.24), 0.88 (95% CI, 0.69-1.12), and 1.27 (95% CI, 0.94-1.71), respectively. There were no significant associations between carbonyl level and risk when analyzing high-grade and low-grade disease separately, nor did finasteride affect protein oxidation levels. The results of this large nested case-control study do not support the hypothesis that oxidative stress, at least as measured by protein carbonyl level, plays a role in prostate cancer.
AB - To evaluate the role of oxidative stress in prostate cancer risk, we analyzed serum levels of protein carbonyl groups in 1,808 prostate cancer cases and 1,805 controls, nested in the Prostate Cancer Prevention Trial, a randomized, placebo-controlled trial that found finasteride decreased prostate cancer risk. There were no significant differences in protein carbonyl levels in baseline samples between those later diagnosed with prostate cancer and those without at the end of study biopsy. Adjusted odds ratios and 95% confidence intervals (95% CI) for the 4th quartile of protein carbonyl level for the combined, placebo, and finasteride arms were 1.03 (95% CI, 0.85-1.24), 0.88 (95% CI, 0.69-1.12), and 1.27 (95% CI, 0.94-1.71), respectively. There were no significant associations between carbonyl level and risk when analyzing high-grade and low-grade disease separately, nor did finasteride affect protein oxidation levels. The results of this large nested case-control study do not support the hypothesis that oxidative stress, at least as measured by protein carbonyl level, plays a role in prostate cancer.
UR - http://www.scopus.com/inward/record.url?scp=77950851969&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77950851969&partnerID=8YFLogxK
U2 - 10.1158/1940-6207.CAPR-09-0201
DO - 10.1158/1940-6207.CAPR-09-0201
M3 - Article
C2 - 20332306
AN - SCOPUS:77950851969
VL - 3
SP - 478
EP - 483
JO - Cancer Prevention Research
JF - Cancer Prevention Research
SN - 1940-6207
IS - 4
ER -